Literature DB >> 11218154

Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer.

M K Tuxen1, G Sölétormos, G J Rustin, A E Nelstrop, P Dombernowsky.   

Abstract

Despite the availability of serial data on CA 125 in ovarian cancer, the problem of interpreting a change over time is still unsolved. Changes in marker concentrations are due not only to patients improving or deteriorating but also to analytical imprecision and normal intra-individual biological variation. The aim of this study was to assess the analytical imprecision (CV(A)) and the intra- and inter-individual biological variation (CV(I) and CV(G), respectively) of CA 125 in a group of 26 patients with clinically stable ovarian cancer. Furthermore, the critical difference for a change between two consecutive CA 125 concentrations calculated as square root(2) x Z x (CV(A)2 + CV(I)2)(1/2) (Z =1.65 for unidirectional and 1.96 for bidirectional changes, p < or = 0.05) and the index of individuality calculated as ((CV(A)2+CV(I)2)/CV(G)2)(1/2) were estimated. After the exclusion of outliers, CV(A) and the average CV(I) and CV(G) were 12.1%, 24.0%, and 43.1%, respectively. The index of individuality was 0.62 and the critical difference calculated for unidirectional changes was 62.6%. CV(A) and CV(I) contribute considerably to the variation in serial results and should, therefore, be included in the criteria for serum tumor marker assessment during monitoring of patients with ovarian cancer. The cut-off value of CA 125 is of minor value in detecting unusual results for an individual subject, when previous measurements from an individual are available. These measurements should be preferred as reference for interpretation of new results.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11218154     DOI: 10.1080/00365510050216448

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  6 in total

1.  Measuring the intra-individual variability of the plasma proteome in the chicken model of spontaneous ovarian adenocarcinoma.

Authors:  Adam M Hawkridge; Rebecca B Wysocky; James N Petitte; Kenneth E Anderson; Paul E Mozdziak; Oscar J Fletcher; Jonathan M Horowitz; David C Muddiman
Journal:  Anal Bioanal Chem       Date:  2010-07-17       Impact factor: 4.142

Review 2.  Ovarian cancer: the duplicity of CA125 measurement.

Authors:  Amer K Karam; Beth Y Karlan
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

3.  Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.

Authors:  Michèl Schummer; Charles Drescher; Robin Forrest; Shirley Gough; Jason Thorpe; Ingegerd Hellström; Karl Erik Hellström; Nicole Urban
Journal:  Gynecol Oncol       Date:  2011-12-07       Impact factor: 5.482

Review 4.  The chicken model of spontaneous ovarian cancer.

Authors:  Adam M Hawkridge
Journal:  Proteomics Clin Appl       Date:  2014-10       Impact factor: 3.494

5.  Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.

Authors:  M K Tuxen; G Sölétormos; P Dombernowsky
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

6.  Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer.

Authors:  Szymon Piatek; Grzegorz Panek; Zbigniew Lewandowski; Dominika Piatek; Przemyslaw Kosinski; Mariusz Bidzinski
Journal:  Sci Rep       Date:  2021-09-14       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.